Refine by
Genome Software In Usa Massachusetts
26 software items found
by:Frameshift Labs, Inc. based inBoston, MASSACHUSETTS (USA)
Mosaic is a collaborative platform for organizing, visualizing, and understanding genomic ...
by:SOPHiA Genetics based inBoston, MASSACHUSETTS (USA)
Deeper genomic insights, fewer missed opportunities. CGP enables clinical researchers to identify actionable variants and biomarkers across hundreds of genes using a single solution. The SOPHiA DDMTM Platform offers decentralized, in-house next generation sequencing (NGS) applications that help maximize insights from CGP data by leveraging advanced analytical capabilities, ...
by:SOPHiA Genetics based inBoston, MASSACHUSETTS (USA)
Next-generation sequencing (NGS) has the potential to revolutionize the diagnosis and treatment of cancers and rare diseases but creates extremely large, complex, and noisy datasets for analysis. Without the right analytical technology, pinpointing causative variants and obtaining actionable insights from NGS data requires specialist skills, multiple resources, and considerable time. The ...
by:SOPHiA Genetics based inBoston, MASSACHUSETTS (USA)
Alamut Visual Plus™ enables deep assessment of variants on a genomic scale, empowering clinical researchers to make accurate decisions for their data interpretation. Alamut Visual Plus™ is a full genome browser designed to help researchers investigate variations of the human genome. The software combines a wide set of external data ...
by:Seven Bridges Genomics based inCharlestown, MASSACHUSETTS (USA)
The representation of the human reference genome as a linear haploid DNA sequence poses limitations when trying to incorporate the known genetic diversity of human populations. This has led to the development of graph-based references, able to naturally represent all polymorphisms, including insertions, deletions, and structural ...
by:SOPHiA Genetics based inBoston, MASSACHUSETTS (USA)
Clinical interpretation has been one of the most complex and time-consuming aspects of transforming genomic data into meaningful results, until ...
by:TriNetX, LLC based inCambridge, MASSACHUSETTS (USA)
With Explore Cohort, review the prevalence of diagnoses, treatments, and procedures among your cohort, retrieve lab value means and standard deviations, and count instances of variants by genome. Use Criteria Analysis to rank order your query criteria by the number of patients they disqualify. Rate of Arrival predicts the volume of new patients who will meet your criteria in the ...
by:SOPHiA Genetics based inBoston, MASSACHUSETTS (USA)
Identifying patterns of genomic scarring in ovarian cancer samples. Accurate identification and reporting of Homologous Recombination Deficiency (HRD) status are critical for better patient management. SOPHiA DDM Dx HRD Solution is a CE-marked in vitro diagnostic (IVD) application leveraging low-pass Whole Genome Sequencing (WGS) and a proprietary deep-learning ...
by:Seven Bridges Genomics based inCharlestown, MASSACHUSETTS (USA)
It is a central hub for teams to store, analyze, and jointly interpret their bioinformatic data. The Platform co-locates analysis pipelines alongside the largest genomic datasets to optimize processing. It allocates storage and compute resources on demand, to meet the needs of ever-growing ...
by:TriNetX, LLC based inCambridge, MASSACHUSETTS (USA)
Data sourced from the EHRs of U.S. healthcare organizations forms the foundation of this combined data asset, providing a rich clinical picture of patients from encounters with providers, lab results, procedures, medication orders, and genomics. Medical and pharmacy claims provide insight into a patient’s care before and after these encounters, regardless of provider. ...
by:SOPHiA Genetics based inBoston, MASSACHUSETTS (USA)
Evaluating the predisposition to develop inherited cancer depends on the ability to characterize genes and alterations associated with increased cancer risk accurately. Next-generation sequencing (NGS) is transforming the way genomic evaluation of hereditary cancers is performed and integrated into the daily workflow of clinical ...
by:SOPHiA Genetics based inBoston, MASSACHUSETTS (USA)
Evaluating the predisposition to develop inherited cancer depends on the ability to characterize genes and alterations associated with increased cancer risk accurately. Next-generation sequencing (NGS) is transforming the way genomic evaluation of hereditary cancers is performed and integrated into the daily workflow of clinical ...
by:SOPHiA Genetics based inBoston, MASSACHUSETTS (USA)
Genomic profiling is driving precision oncology. From targeted to comprehensive solutions, Next-Generation-Sequencing (NGS) offers the capacity to simultaneously analyze a select set of genes, regions, and biomarkers based on known involvement across solid tumor such as lung, colon, breast, melanoma, gastric, and ovarian cancers. ...
by:SOPHiA Genetics based inBoston, MASSACHUSETTS (USA)
Bring liquid biopsy to your lab with our streamlined DNA-only NGS workflow, taking you from cell-free DNA sample to comprehensive report in record time. Powered by state-of-the-art proprietary algorithms, the SOPHiA DDMTM Platform reveals deep genomic insights from cell-free DNA, advancing your oncology research to new ...
by:SOPHiA Genetics based inBoston, MASSACHUSETTS (USA)
Push the boundaries of your in-house liquid biopsy capabilities with MSK-ACCESS® powered with SOPHiA DDM™, a decentralized version of the rigorously validated cell-free DNA (cfDNA) assay developed and used in clinical routine by Memorial Sloan Kettering Cancer Center (MSK)1,2. Discover an innovative solution that combines MSK’s expertise in cancer genomics with ...
by:SOPHiA Genetics based inBoston, MASSACHUSETTS (USA)
Next-generation sequencing (NGS) of the human exome has the potential to identify pathogenic variants responsible for complex phenotypes associated with rare ...
by:SOPHiA Genetics based inBoston, MASSACHUSETTS (USA)
Metabolic disorders are a major cause of morbidity and mortality, representing a growing health concern worldwide. Over the last decade, substantial progress has been made in the discovery of genetic variants influencing a range of metabolic diseases.1 The advances in next generation sequencing (NGS) technologies have contributed to elucidation of the pathogenic role of variants associated with ...
by:SOPHiA Genetics based inBoston, MASSACHUSETTS (USA)
Cardiac diseases are the #1 cause of death globally1,2. Genetic testing is frequently considered a key component of the clinical management process of inherited cardiac disorders, such as hypertrophic, dilated, and arrhythmogenic cardiomyopathies, aortopathies, and inherited arrhythmia syndromes3. This approach is typically reserved for patients with a confirmed or suspected diagnosis of an ...
by:SOPHiA Genetics based inBoston, MASSACHUSETTS (USA)
Hematological tumors represent the fourth most frequent cancer type in the developed world. In addition to the continuously evolving clinical guidelines2, harnessing of all the available information when investigating hematological disorders into meaningful insights can be outdated, inaccurate, costly, and time-consuming. This ultimately risks limiting researchers’ productivity, thus ...
by:SOPHiA Genetics based inBoston, MASSACHUSETTS (USA)
Maximize your biologically actionable insights from small tumor samples with the SOPHiA DDM™ RNAtarget Technology end-to-end solutions. Gene fusions have been associated with various tumors and are recognized as valuable cancer biomarkers in cancer research1. Targeted RNA sequencing is recommended to maximize novel fusion detection by identifying transcribed and potentially actionable ...